Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Dialectic Therapeutics Inc.

Headquarters: Dallas , TX, United States of America
Year Founded: 2018
Status: Private

BioCentury | Feb 10, 2023
Discovery & Translation

Targeting PIKFYVE and SYF2 for ALS; plus new protein degraders and more

BioCentury's roundup of translational news
BioCentury | Dec 3, 2021
Discovery & Translation

Mapping the plasma proteome to identify drug targets; plus GSK-Vir, Codiak and more

BioCentury’s roundup of translational news
BioCentury | Jan 30, 2020
Distillery Therapeutics

Targeted Bcl-XL degrader identified to treat ALL, TNBC and SCLC

BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

A dive into the ASH 2018 abstracts highlights cancer metabolism as a top focus
Items per page:
1 - 4 of 4